ImmuPharma shares rose on Friday after providing an update on P140, its autoimmune technology platform, pointing to progress on three fronts: patents, supporting data, and a forthcoming scientific publication.
The company has received its first Combined Search and Examination Report on a UK patent application for P140, filed in September 2025. Management describes the response as supportive and in line with expectations at this stage. ImmuPharma plans to follow up with a Patent Cooperation Treaty application to seek protection across key commercial territories.
ImmuPharma shares were 13% higher at the time of writing.
Alongside the patent process, the company has completed a new study designed to stress-test P140’s associated diagnostic test and bolster the statistical strength of its dataset. The results came back positive and supportive of the application.
The scientific team, led by CSO Dr. Sébastien Goudreau and Head of R&D Dr. Laura Mauran, is now preparing a manuscript on P140’s technology platform and mechanism of action for submission to a peer-reviewed journal. The company intends to share the findings more widely with the scientific community once published.
On the commercial front, ImmuPharma says partnering discussions are ongoing with several potential partners, some of whom are under signed confidentiality agreements.
The team was in Lisbon this week at Bio-Europe Spring, where it held a number of P140-related meetings. The company says it remains focused on securing a licensing deal in 2026. Investors will watch with interest.